|
gptkbp:instanceOf
|
gptkb:drug
proton pump inhibitor
|
|
gptkbp:approvedBy
|
1994
|
|
gptkbp:ATCCode
|
gptkb:A02BC02
|
|
gptkbp:availableOn
|
gptkb:tablet
injection
|
|
gptkbp:bioavailability
|
77%
|
|
gptkbp:brand
|
gptkb:Pantoloc
gptkb:Somac
gptkb:Protonix
|
|
gptkbp:CASNumber
|
102625-70-7
|
|
gptkbp:category
|
gptkb:essential_medicine_(WHO)
|
|
gptkbp:color
|
white to off-white
|
|
gptkbp:contraindication
|
hypersensitivity to pantoprazole
|
|
gptkbp:discoveredBy
|
gptkb:Byk_Gulden
|
|
gptkbp:drugClass
|
proton pump inhibitor
|
|
gptkbp:eliminationHalfLife
|
about 1 hour
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
powder for injection
delayed-release tablet
|
|
gptkbp:hasMolecularFormula
|
C16H15F2N3O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pantoprazole
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:clopidogrel
gptkb:methotrexate
gptkb:atazanavir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits H+/K+ ATPase in gastric parietal cells
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:origin
|
gptkb:Germany
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:riskFactor
|
may cause low magnesium with long-term use
may increase risk of bone fracture with long-term use
may increase risk of Clostridium difficile infection
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
dizziness
headache
|
|
gptkbp:solubility
|
freely soluble in water
|
|
gptkbp:synonym
|
gptkb:pantoprazole_magnesium
gptkb:pantoprazole_sodium
|
|
gptkbp:usedFor
|
gptkb:Zollinger-Ellison_syndrome
gptkb:gastroesophageal_reflux_disease
gptkb:peptic_ulcer_disease
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|